Advertisement

Topics

Acceleron Pharma, Inc. Company Profile

07:10 EDT 23rd March 2019 | BioPortfolio

Acceleron is a privately held biopharmaceutical company committed to discover, develop, manufacture and commercialize novel biotherapeutics that modulate the growth of red blood cells, bone, muscle, fat and the vasculature to treat musculoskeletal, metabolic and cancer-related diseases. Acceleron’s scientific approach takes advantage of its unique insight into the regenerative powers of the TGF-β superfamily of proteins. ACE-011 is in a Phase 2 clinical trial in patients with anemia. ACE-031 is being studied in a Phase 2 clinical trial in patients with Duchenne Muscular Dystrophy and ACE-041 is being studied in a Phase 1 clinical trial in patients with advanced cancer. In addition, the company is developing several other new product candidates that increase muscle mass, control angiogenesis, inhibit fat accumulation and increase bone mass and strength. Acceleron utilizes proven biotherapeutic technologies and capitalizes on the company’s internal GMP manufacturing capability to rapidly and efficiently advance its therapeutic programs. The investors in Acceleron include Advanced Technology Ventures, Alkermes, Bessemer Ventures, Celgene, Flagship Ventures, MPM BioEquities, OrbiMed Advisors, Polaris Ventures, QVT Financial, Sutter Hill Ventures and Venrock. For more information, visit www.acceleronpharma.com

Location

24 Emily Street
Cambridge
Massachusetts
02139
United States of America

Contact

Phone: 617-576-2220
Fax: 617-576-2224
Email: info@acceleronpharma.com


News Articles [738 Associated News Articles listed on BioPortfolio]

Acceleron nets $216.2mm via FOPO

Acceleron Pharma Inc. netted $216.2mm in a follow-on public offering of 5.35mm common shares at $42 each. The company plans to use the proceeds for clinical trials of its pulmonary hypertension and ne...

'Totality Of Data' Make A Case For Luspatercept In Beta-Thalassemia, MDS

Acceleron/Celgene’s drug was effective across all endpoints in transfusion-dependent beta-thalassemia and myelodysplastic syndromes, but Acceleron CEO Habib Dable notes key...   

FDA fast-tracks Acceleron's Charcot-Marie-Tooth disease candidate

FDA fast-track status was given to Acceleron Pharma's Charcot-Marie-Tooth disease drug candidate ACE-083, which is in midstag -More- 

Acceleron Pharma Inc. 2018 Q4 - Results - Earnings Call Slides

Acceleron Pharma Inc. 2018 Q3 - Results - Earnings Call Slides

Acceleron to Webcast Third Quarter 2018 Operating and Financial Results on October 30, 2018

Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Tuesday, October 30, 2018 at 4:30 p.m. EDT to discuss its third quarter 2018 oper...

STAT Plus: The benefit of a blood disease drug from Acceleron and Celgene debated by experts

If cleared, it will be Acceleron’s first marketed drug — and good news for Celgene, damaged by a string of clinical and commercial setbacks.

Acceleron to Webcast Fourth Quarter and Full Year 2018 Operating and Financial Results on February 27, 2019

Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Wednesday, February 27, 2019 at 5:00 p.m. EST to discuss its fourth quarter and f...

Drugs and Medications [53 Associated Drugs and Medications listed on BioPortfolio]

Fluoride [mayne pharma inc]

Fluoride Chewable Tablets 0.5 mg

Fluoride [mayne pharma inc]

Fluoride Chewable Tablets 1 mg

Urea [mayne pharma inc.]

Rx Only 45% Urea Nail Gel In a vehicle containing Camphor, Eucalyptus Oil and Menthol )

Eloxatin [aventis pharma ltd.]

NA

Ribavirin [aurobindo pharma limited]

NA

PubMed Articles [21 Associated PubMed Articles listed on BioPortfolio]

Establishing and Maintaining a Robust Sample Management System.

This paper has been written by the SLAS Sample Management Special Interest Group to serve as a guide to the best practices and methods in establishing and maintaining a high-quality sample management ...

Disease awareness advertising (DAA) in emerging economy: A comparison between views of consumers and pharmaceutical professionals.

Research on effectiveness of DAA is limited. Existing researches explore impact of DAA only on relationship between drug manufacturers and consumers. However, in reality, pharma marketing revolves aro...

21 Century Citizen Pharma: The FDA & Patient-Focused Product Development.

Perpetual debate regarding the delicate balance between access and innovation and the protection of the public health and safety dominate discussions of the United States Food and Drug Administration ...

CVS and the $100,000 QALY.

The PBM unit of the health giant CVS decided that any new drug exceeding $100,000 per quality-adjusted life year (QALY) may be excluded from the formularies that are maintained by its clients. Patient...

The Common Pharmaceutical Market of the Eurasian Economic Union: A Regulatory Review.

According to the Treaty on the Eurasian Economic Union, a common pharmaceutical market was supposed to become operational on January 1, 2016. Nevertheless, the responsible parties did not meet the dea...

Clinical Trials [88 Associated Clinical Trials listed on BioPortfolio]

Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (9.5mg/24h)

The present clinical trial will be conducted in order to compare the bioavailability of rivastigmine and to assess bioequivalence at steady-state of the Test product RID-TDS 9.5 mg/24 h (L...

To Demonstrate the Relative Bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam Tablets In Healthy Adults Volunteers Under Fasting Conditions

To demonstrate the relative bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam tablets in healthy adult volunteers under fasting conditions.

Pharma-Pen (Formerly Innoject) Auto-Injectory TIV

The purpose of this study is to evaluate the safety, effectiveness, and tolerability, of the Pharma-Pen(TM) intramuscular (IM) and subcutaneous (SC) auto-injector systems used by untrained...

A Bioequivalence Study of Cefadroxil From Duricef 1 gm F.C.T (GSK) and Biodroxil 1 gm F.C.T (Novartis Pharma)

Comparative randomized, single dose, two-way crossover open-label study to determine the bioequivalence of Cefadroxil from Duricef 1 gm Film Coated tablets(Smthkline Beecham Egypt,LLC aff...

Steady State Global Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg/ Vial in Fed Condition

The primary objective is to determine clinical bioequivalence of Amphotericin B liposome for injection of Auromedics Pharma LLC, USA and AmBisome (Amphotericin B) liposome for injection of...

Companies [801 Associated Companies listed on BioPortfolio]

Acceleron Pharma, Celgene Corporation

Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth a...

Acceleron Pharma & Celgene Corporation

Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth a...

Acceleron Pharma Inc.

Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases. The...

Acceleron Pharma and Celgene Corporation

Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases. The...

Acceleron Pharma, Inc.

Acceleron is a privately held biopharmaceutical company committed to discover, develop, manufacture and commercialize novel biotherapeutics that modulate the growth of red blood c...

More Information about "Acceleron Pharma, Inc." on BioPortfolio

We have published hundreds of Acceleron Pharma, Inc. news stories on BioPortfolio along with dozens of Acceleron Pharma, Inc. Clinical Trials and PubMed Articles about Acceleron Pharma, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Acceleron Pharma, Inc. Companies in our database. You can also find out about relevant Acceleron Pharma, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Blood
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...

Osteoporosis
Osteoporosis is a disease in which the bones become extremely porous, are subject to fracture, and heal slowly, occurring especially in women following menopause and often leading to curvature of the spine from vertebral collapse. Follow and track&n...


Corporate Database Quicklinks



Searches Linking to this Company Record